Tempus AI (TEM) Enterprise Value to EBITDA Ratio
Risks for Tempus AI, Inc (TEM) are linked to revenue volatility from sequencing and data sales to pharma behemoths. The company's EV/EBITDA trajectory visualizes these fluctuations, and the metric has now reached 0.00. Stability is driven by the monetization of AI diagnostics and personalized treatment. Business resilience is guaranteed by a unique clinical data base, which creates a powerful defensive moat against competitors in the precision medicine sector.
Comprehensive metric breakdowns and analytics for Tempus AI (TEM)
- market price and analyst price targets:
- market capitalization details:
- business book valuation details:
- debt and solvency information:
Total Debt to Equity Ratio Tempus AI, Inc|TEM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Tempus AI, Inc.|TEM - Company Total Debt Obligations|Debt to Book Capitalization Ratio Tempus Labs|TEM - Company Long-Term Indebtedness|Company Short-Term Debts Tempus|Quick Liquidity Indicator tempus.com
- financial results and valuation multiples details:
TEM - Profit After Payment of Taxes|Projected Future Earnings Tempus AI, Inc|TEM - Market Cap to Earnings|Future Price to Earnings Tempus AI, Inc|TEM - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Tempus Labs|TEM - Operating profit before amortization|Earnings per share for the last twelve months Tempus|TEM - Earnings per share for the last 12 months|Quarterly EPS earnings growth tempus.com|TEM - Earnings growth in current year|Expected earnings per share growth for next year Tempus AI, Inc
Comprehensive company analysis:TEM (Tempus Labs)
Tempus AI, Inc (TEM) is developing medical AI in the US while facing stringent regulations on the cross-border exchange of genetic data. The company's EV/EBITDA ratio over the time series reflects the total business value relative to its operating profit before depreciation and taxes. This metric allows for an assessment of capital efficiency amid a high debt load. Abnormal spikes in the indicator signal an asset overvaluation and increasing risks of a drawdown.
Competitor analysis for Tempus AI, Inc
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Qiagen Group QGEN|Total Company Value to Operating Income Before Depreciation Ratio Isis Pharmaceuticals (IONS)|RGEN: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RNA (aviditybiosciences.com)|CRSP: EV/EBITDA Multiple|GeneDx Holdings (WGS) - EV/EBITDA Multiple|RARE (Ultragenyx Pharma) - EV/EBITDA Multiple|Beam Tx (BEAM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio SRPT (Sarepta Therapeutics, Inc.)|TWST (twistbioscience.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TXG (10x Genomics)|Total Company Value to Operating Income Before Depreciation Ratio Intellia Therapeutics Inc (NTLA)|STOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BLFS (BioLife) - Enterprise Value to Operating Income Before Depreciation|WVE: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio mazetx.com|Enterprise Value to EBITDA Ratio SION|PRME (Prime Medicine Inc) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple TSHA|QURE - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx Holdings plc MGTX|RGNX - Enterprise Value to EBITDA Ratio|Solid Biosciences - EV/EBITDA Multiple|OCGN (Ocugen Inc) - Enterprise Value to Operating Income Before Depreciation|Pacific Biosciences of California (PACB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BNTC|DSGN (Design Therapeutics) - EV/EBITDA Multiple|EV/EBITDA Multiple rocketpharma.com|Enterprise Value to EBITDA Ratio FDMT (4D Molecular Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio LXEO|EV/EBITDA Multiple KRRO (Korro Bio)|Editas Corp (EDIT) - Company Value to EBITDA|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ProQR Therapeutics N.V. (PRQR) - Enterprise Value to EBITDA Ratio|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio SGMO (Sangamo Therapeutics Inc.)|Enterprise Value to EBITDA Ratio NAUT|EV/EBITDA Multiple Metagenomi Therapeutics|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|Total Company Value to Operating Income Before Depreciation Ratio generationbio.com|Boundless Bio - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation XCUR|Celsion Corporation - EV/EBITDA Multiple|PHIO - EV/EBITDA Multiple|MBIO: EV/EBITDA Multiple|RNAZ - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio BNGO|APDN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BLUE|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|OMIC: Enterprise Value to Operating Income Before Depreciation|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Syros Pharmaceuticals Inc. (SYRS) - Enterprise Value to EBITDA Ratio|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|TCON: Enterprise Value to Operating Income Before Depreciation Ratio|UBX (Unity Biotechnology) - EV/EBITDA Multiple
